相关实验视频

Updated: Jun 10, 2025

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

医用大麻持卡人身份与抗药物过度使用之间的关联

Alan P Baltz¹, Cheng Peng², Laura Gressler²

¹Department of Internal Medicine, Division of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

Cannabis and cannabinoid research

|October 17, 2024

概括

医用大麻 (MMJ) 卡持有者与非卡持有者相比,不太可能过度使用化疗诱导的恶心和吐 (CINV) 的抗药. 这表明MMJ可能有助于控制CINV症状,并减少癌症患者过度使用抗药.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
公共卫生公共卫生

背景情况:

美国临床瘤学会 (ASCO) 建议在化疗引起的恶心和吐 (CINV) 时明智地处方抗药.
医用大麻 (MMJ) 具有潜在的抗性质,但其对癌症患者抗使用的影响尚不清楚.

研究的目的:

调查MMJ卡持有人身份是否与癌症患者过度使用抗药物有关.
评估MMJ接入与遵守ASCO对抗吐药物处方指南之间的关系.

主要方法:

基于人口的队列 (20,558名癌症患者) 的回顾性分析,使用链接的医疗保健索赔和MMJ注册表数据 (2013-2020).
暴露被定义为MMJ卡持有人身份;主要结局是基于ASCO建议的抗药物过度使用.
多变量后勤回归调整了人口和临床因素,以确定抗发药物过度使用的几率比率.

主要成果:

与非卡持有者相比,MMJ卡持有者 (2.1%的队列) 经历抗药物过度使用的可能性明显低 (aOR:0.76,p < 0.001).
在7.5%的化疗周期中,过度使用抗药物发生了.
诸如化疗周期较少,年龄较小,化疗途径,CINV风险和癌症类型等因素影响了抗emetic过度使用风险.

结论:

在接受化疗的癌症患者中,MMJ卡持有人身份与抗药物过度使用的可能性降低有关.
需要进一步的研究来探索大麻对CINV管理的有效性和安全性,以指导临床实践.

关键词:

抗的过度使用.癌症癌症癌症癌症癌症大麻大麻大麻大麻大麻大麻大麻大麻化疗引起的恶心和吐.医用大麻医用大麻医用大麻恶心和吐,以及恶心和吐.

更多相关视频

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture

Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture

Published on: August 4, 2023

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Cholinergic Antagonists: Therapeutic Uses

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...

Pathophysiology of Vomiting

Pathophysiology of Vomiting

Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through...